Researchers have identified a significant blind spot in how doctors treat stubborn high blood pressure: nearly 3 in 10 patients with resistant hypertension may be struggling with elevated cortisol levels that go undetected.
The finding comes from a major U.S. study examining why certain patients fail to respond to standard blood pressure medications. The hormone cortisol, typically associated with the body's stress response, appeared in abnormally high concentrations in 27% of these hard-to-treat cases—a rate substantially above what would occur by chance.
The discovery suggests that conventional approaches to managing resistant hypertension may overlook a treatable metabolic condition. When cortisol remains elevated, it can interfere with the effectiveness of antihypertensive drugs and prevent blood pressure from reaching target levels, even when patients take multiple medications as prescribed.
This hormonal imbalance represents a concrete diagnostic opportunity. Testing for elevated cortisol in patients whose blood pressure resists standard treatment could unlock new pathways to care. Rather than simply adding more medications or increasing doses, clinicians might address the underlying hormonal dysfunction driving the hypertension.
The implications extend beyond diagnosis. Identifying cortisol as a contributor to treatment-resistant high blood pressure opens the door to targeted interventions designed specifically for this subgroup of patients. The condition is both recognizable through testing and potentially manageable once confirmed.
For the millions of Americans struggling to control their blood pressure despite medication, the research offers a concrete reason to ask their doctors about hormone screening. What appears to be a medication failure may instead reflect a physiological problem that has simply gone unrecognized.
Comments